https://www.thebodypro.com/category/complera-pro

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (Complera)

The Latest

hole in a fence
News

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds Img
News

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds

The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.

Can Antiretrovirals Help Those Who Control HIV Naturally? Img
News

Can Antiretrovirals Help Those Who Control HIV Naturally?

The more we learn about "HIV controllers," the more we realize that they may not actually be "controlling" their HIV infection quite as well as we'd thought.

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds Img
News

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds

Many people who had high lipid levels while taking common HIV treatment regimens that included a protease inhibitor, such as Prezista or Reyataz, saw remarkable improvements after the switch.

Promo Image
News

Complera Labeling Update: No Longer Recommended at High Viral Loads; Hepatotoxicity Precaution Added

On January 25, 2013, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) package insert. The major changes include restricting the indication to treatment-naive adult patients with HIV-1 RNA less than or equ...

Promo Image
Conference Coverage

HIV Drug Updates

Complera, the newest single tablet regimen (STR), comprised of rilpivirine (Edurant) plus emtricitabine/tenofovir (Truvada), continues to hold its own. Previously, it had been shown to be non-inferior to Atripla, another STR, made of efavirenz (Susti...

Promo Image
News

Complera and Atripla News

Last summer, 48-week data won FDA approval for Complera (see the November/December 2011 "Briefly" for the complicated details). At IDSA, 96-week data were presented from the ECHO and THRIVE studies that pitted the new Complera against Atripla. Comple...

Promo Image
News

Switching From Atripla to Complera

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here bec...

Promo Image
News

The Path to a Cure

Is curing HIV possible? I believe that the answer is a resounding YES! The proof of concept for a cure is derived from the famous Berlin patient, Timothy Ray Brown, who many now believe has been "cured." Also, at least two small pharmaceutical compan...

Top 10 HIV/AIDS-Related Clinical Developments of 2011 Img
Women

Top 10 HIV/AIDS-Related Clinical Developments of 2011

David Wohl, M.D., takes an in-depth look at this year's most critical HIV-related studies, and explains how each one may change how we prevent and treat HIV in 2012 and beyond. (Fair warning: This article can get pretty technical, but each story has ...